Jean-François Labbé
Président chez NICOX SA
Profil
Jean-François Labbé founded OTL Pharma SA in 2001, where he worked as Chief Executive Officer from 2001 to 2004 and SpePharm Holding BV in 2006, where he worked as Chief Executive Officer & Managing Director from 2011 to 2014.
Mr. Labbé also currently works at Nicox SA, as Chairman from 2022, Centravet, as Chairman-Supervisory Board, and Nicox Ophthalmics, Inc., as Director from 2010.
Mr. Labbé also formerly worked at Parke-Davis & Co. Ltd., as Chief Executive Officer from 1999 to 2001, IDS, as Chairman & Chief Executive Officer, Libragen SA, as Chairman-Supervisory Board, Covadis BV, as Chairman-Supervisory Board, AlgoTherapeutix SAS, as Chairman, Transgene SA, as Independent Director from 2012 to 2018, DrugAbuse Sciences SAS, as Director in 2009, Deinove SA, as Director, Hoechst Marion Roussel SA, as President-Europe, Middle East & Africa in 1999, Pfizer Group Ltd., as President from 1999 to 2001, Hoechst-Roussel Pharmaceuticals, Inc., as Principal, and Kyowa Kirin Ltd., as Chief Operating Officer from 2004 to 2005.
Mr. Labbé received his Masters Business Admin degree from École des Hautes Études Commerciales de Paris.
Postes actifs de Jean-François Labbé
| Sociétés | Poste | Début |
|---|---|---|
| NICOX SA | Président | 28/07/2022 |
Centravet
 Centravet Agricultural Commodities/MillingProcess Industries Centravet operates as a veterinary distribution center, which supplies medicine, food and material practitioners and to promote the veterinary surgeon. It offers TransNet, ivet, GmVet, Pilehairs, and Webveto solutions. The company was founded in 1972 and is headquartered in Taden, France. | Président | - |
Nicox Ophthalmics, Inc.
 Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Directeur/Membre du Conseil | 01/01/2010 |
Anciens postes connus de Jean-François Labbé
| Sociétés | Poste | Fin |
|---|---|---|
| DEINOVE | Directeur/Membre du Conseil | 08/02/2022 |
Algotherapeutix SAS
 Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Président | 01/09/2020 |
| TRANSGENE | Directeur/Membre du Conseil | 01/06/2018 |
SpePharm Holding BV
 SpePharm Holding BV Pharmaceuticals: MajorHealth Technology SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market. Particular therapeutic areas of interest are in oncology and hematology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. The vision of SpePharm is to become a leading specialty pharmacy company offering the first truly pan-European commercial platform for high value niche hospital and specialist products. The company was founded in September 2006 by Jean-François Labbé together with leading life-science investment firms, TVM Capital (Germany) and Signet Healthcare Partners, part of the Sanders Morris Harris Group Inc (USA). SpePharm headquarters are located in Amsterdam, The Netherlands. Its European operations are run from its French subsidiary, SpePharm SAS, in Paris, France. Since January 2008, Spepharm is also present in Europe through subsidiaries in Italy (Milan), Germany (Munich), The United-Kingdom (Oxford) and Denmark (Copenhagen) for the Nordic countries. | Directeur Général | 21/04/2014 |
DrugAbuse Sciences SAS
 DrugAbuse Sciences SAS Pharmaceuticals: MajorHealth Technology DrugAbuse Sciences SAS develops therapies for treatment of alcohol abuse and opiate addiction. It also operates an educational website which is designed to provide clinicians, patients access to information and services related to alcohol abuse treatment and care. The company is headquartered in Lyon, France | Directeur/Membre du Conseil | 01/01/2009 |
Formation de Jean-François Labbé
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| IDS | Technology Services |
| TRANSGENE | Health Technology |
| NICOX SA | Health Technology |
| Entreprise privées | 14 |
|---|---|
SpePharm Holding BV
SpePharm Holding BV Pharmaceuticals: MajorHealth Technology SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market. Particular therapeutic areas of interest are in oncology and hematology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. The vision of SpePharm is to become a leading specialty pharmacy company offering the first truly pan-European commercial platform for high value niche hospital and specialist products. The company was founded in September 2006 by Jean-François Labbé together with leading life-science investment firms, TVM Capital (Germany) and Signet Healthcare Partners, part of the Sanders Morris Harris Group Inc (USA). SpePharm headquarters are located in Amsterdam, The Netherlands. Its European operations are run from its French subsidiary, SpePharm SAS, in Paris, France. Since January 2008, Spepharm is also present in Europe through subsidiaries in Italy (Milan), Germany (Munich), The United-Kingdom (Oxford) and Denmark (Copenhagen) for the Nordic countries. | Health Technology |
Covadis BV
 Covadis BV Packaged SoftwareTechnology Services Covadis BV provides tailor-made software development services. The company is headquartered in Doetinchem, the Netherlands. | Technology Services |
OTL Pharma SA
 OTL Pharma SA Pharmaceuticals: MajorHealth Technology Part of Kirin Holdings Co., Ltd., OTL Pharma SA is a French company that develops and markets pharmaceutical products in the therapeutic areas of oncology, hematology, neurology, and supportive and intensive care. The company is based in Paris, France. The company was founded by Marc Moguilewsky, Jean-François Labbé, Wim van Bree. OTL Pharma was acquired by Strakan Group Ltd. on January 26, 2004 for $8.92 million. | Health Technology |
Parke-Davis & Co. Ltd.
 Parke-Davis & Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Parke-Davis & Co. Ltd. is a British pharmaceutical company. The company is based in St. Helier, UK. | Health Technology |
| Hoechst-Roussel Pharmaceuticals, Inc. | |
Libragen SA
 Libragen SA BiotechnologyHealth Technology Libragen SA develops bioprocesses for the industrial production of healthcare molecules. The firm engages in the cosmetic chemical sciences by carrying out research for the discovery and development of cosmetic ingredients. The company was founded by Renaud Nalin in 2001 and is headquartered in Toulouse, France. | Health Technology |
DrugAbuse Sciences SAS
DrugAbuse Sciences SAS Pharmaceuticals: MajorHealth Technology DrugAbuse Sciences SAS develops therapies for treatment of alcohol abuse and opiate addiction. It also operates an educational website which is designed to provide clinicians, patients access to information and services related to alcohol abuse treatment and care. The company is headquartered in Lyon, France | Health Technology |
| Hoechst Marion Roussel SA | Health Technology |
Kyowa Kirin Ltd.
 Kyowa Kirin Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1998, Kyowa Kirin Ltd. is a British pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. Part of Kirin Holdings Co., Ltd., the company is based in London, UK. | Health Technology |
Deinove SA
 Deinove SA BiotechnologyHealth Technology Deinove SA is a biotechnology company, which engages in the development of new-generation anti-infective antibiotics and bioactives. Its portfolio include Phy-N-Resist and HEBELYS. The company was founded by Philippe Pouletty and Miroslav Radman on October 11, 2006 and is headquartered in Grabels, France. | Health Technology |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Health Technology |
Centravet
Centravet Agricultural Commodities/MillingProcess Industries Centravet operates as a veterinary distribution center, which supplies medicine, food and material practitioners and to promote the veterinary surgeon. It offers TransNet, ivet, GmVet, Pilehairs, and Webveto solutions. The company was founded in 1972 and is headquartered in Taden, France. | Process Industries |
Pfizer Group Ltd.
 Pfizer Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Group Ltd. is a British company that manufactures and sells pharmaceuticals, animal health products, and healthcare products. The company is based in Sandwich, UK. | Health Technology |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Health Technology |
